Holen Sie sich die Stockscreener-App
1.32
0.76%
0.01
Schlusskurs vom Vortag:
$1.31
Offen:
$1.29
24-Stunden-Volumen:
91,970
Relative Volume:
0.23
Marktkapitalisierung:
$5.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.40M
KGV:
-8.25
EPS:
-0.16
Netto-Cashflow:
$-9.08M
1W Leistung:
-9.59%
1M Leistung:
-23.70%
6M Leistung:
-79.04%
1J Leistung:
-87.89%
1-Tages-Spanne:
$1.27
$1.32
1-Wochen-Bereich:
$1.25
$1.471
52-Wochen-Spanne:
$1.25
$15.06
Alzamend Neuro Inc Stock (ALZN) Company Profile
Firmenname
Alzamend Neuro Inc
Sektor
Branche
Telefon
844-722-6333
Adresse
3500 LENOX RD. NE, ATLANTA
Vergleichen Sie ALZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ALZN | 1.31 | 5.77M | 0 | -12.40M | -9.08M | -0.16 |
| VRTX | 449.64 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-01 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Alzamend reports promising results for brain-targeted lithium therapy - Investing.com India
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice - Business Wire
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential - Yahoo Finance
Alzamend Neuro stock hits 52-week low at $1.39 amid sharp decline - Investing.com
Alzamend Neuro sets trial dosage for AL001 lithium therapy - Alzheimer's News Today
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s - BioSpace
Alzamend Neuro advances Alzheimer's treatment with new lithium dose - Investing.com
Alzamend Neuro advances Alzheimer's treatment with new lithium dose By Investing.com - Investing.com South Africa
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's - Yahoo Finance
Alzamend Neuro Inc (ALZN) receives a Buy rating from Ascendiant Capital Markets - Knox Daily
Alzamend Neuro Inc (ALZN) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Alzamend Neuro Inc (ALZN-Q) QuotePress Release - The Globe and Mail
Alzamend Neuro regains Nasdaq compliance with equity rule By Investing.com - Investing.com UK
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards - StockTitan
Alzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42 - MSN
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference - Barchart
Nasdaq Bank Index (BANK) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Alzamend Neuro enters agreement for $6.5 million ATM offering - Investing.com India
Alzamend Neuro enters agreement for $6.5 million ATM offering By Investing.com - Investing.com Australia
Globalfoundries Inc (GFS-Q) QuotePress Release - The Globe and Mail
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) - Knox Daily
Alzamend Neuro Inc: Rising -96.02% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Alzamend Neuro stock hits 52-week low at $1.81 amid market challenges - Investing.com
Understanding the Risks of Investing in Alzamend Neuro Inc (ALZN) - Knox Daily
New partners team up for Phase 2 trial of novel lithium therapy AL001 - Alzheimer's News Today
Ratios Reveal: Breaking Down Alzamend Neuro Inc (ALZN)’s Financial Health - The Dwinnex
Keeping an Eye on Alzamend Neuro Inc (ALZN) After Insider Trading Activity - Knox Daily
Alzamend Neuro Inc (ALZN) is a good investment, but the stock may be overvalued - US Post News
Alzamend Neuro Inc [ALZN] Records 50-Day SMA of $3.50 - Knox Daily
It is Poised to be a Bull Market for Alzamend Neuro Inc (ALZN) - SETE News
Investing in Alzamend Neuro Inc (ALZN): What You Must Know - Knox Daily
Market Momentum: Alzamend Neuro Inc (ALZN) Registers a -7.47 Decrease, Closing at 2.85 - The Dwinnex
Alzamend partners with Mass General for clinical trials - Investing.com
Examining Alzamend Neuro Inc (ALZN) more closely is necessary - US Post News
Alzamend partners with Mass General for clinical trials By Investing.com - Investing.com UK
Alzamend Neuro Issues Letter to Stockholders - StockTitan
ALZN Stock Sees Surge of Approximately 72.96% in Last Five Days - Knox Daily
Daily Market Movement: Alzamend Neuro Inc (ALZN) Sees a -0.91 Decrease, Closing at 4.35 - The Dwinnex
Get in on Alzamend Neuro Inc’s (ALZN) buy-in window today! - SETE News
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board - Quantisnow
Alzamend Neuro Inc [ALZN] Stock trading around $5.85 per share: What’s Next? - The DBT News
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN
Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Quantisnow
Analyzing the Impact of Earnings Reports on Alzamend Neuro Inc Inc. (ALZN) Price Performance - The InvestChronicle
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge - Benzinga
Alzamend Neuro (ALZN) Could Triple from current levels and here’w why - BP Journal
Alzamend Neuro Shares Rise on Partnership for PTSD Treatment Mid-Stage Study - MarketWatch
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alzamend Neuro Inc-Aktie (ALZN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Jul 31 '24 |
Buy |
3.74 |
25 |
93 |
77,193 |
| AULT MILTON C III | Director |
Apr 19 '24 |
Buy |
0.69 |
1,000 |
688 |
771,699 |
| AULT MILTON C III | Director |
Apr 01 '24 |
Buy |
0.91 |
334 |
304 |
770,699 |
| AULT MILTON C III | Director |
Jan 05 '24 |
Buy |
1.06 |
2,000 |
2,127 |
770,365 |
| AULT MILTON C III | Director |
Jan 05 '24 |
Buy |
1.02 |
5,000 |
5,092 |
768,365 |
| AULT MILTON C III | 10% Owner |
Dec 26 '23 |
Buy |
0.90 |
500 |
450 |
26,032 |
| AULT MILTON C III | 10% Owner |
Dec 22 '23 |
Buy |
0.92 |
200 |
185 |
166,866 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):